Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Janux Therapeutics (JANX) Operating Income (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Operating Income for 6 consecutive years, with -$42.4 million as the latest value for Q4 2025.

  • Quarterly Operating Income fell 46.1% to -$42.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$157.7 million through Dec 2025, down 59.51% year-over-year, with the annual reading at -$157.7 million for FY2025, 59.51% down from the prior year.
  • Operating Income for Q4 2025 was -$42.4 million at Janux Therapeutics, down from -$35.3 million in the prior quarter.
  • The five-year high for Operating Income was -$2.3 million in Q1 2021, with the low at -$45.1 million in Q2 2025.
  • Average Operating Income over 5 years is -$21.5 million, with a median of -$18.1 million recorded in 2022.
  • The sharpest move saw Operating Income tumbled 768.07% in 2021, then surged 33.38% in 2024.
  • Over 5 years, Operating Income stood at -$13.5 million in 2021, then tumbled by 35.4% to -$18.3 million in 2022, then increased by 11.66% to -$16.1 million in 2023, then crashed by 79.85% to -$29.0 million in 2024, then tumbled by 46.1% to -$42.4 million in 2025.
  • According to Business Quant data, Operating Income over the past three periods came in at -$42.4 million, -$35.3 million, and -$45.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.